CDK4 and breast cancer: We then analyzed pharmacokinetic characteristics of these candidate drugs using ADMETlab2.0, which indicated that Palbociclib, the first CDK4/6 inhibitor for breast cancer treatment with efficient blood–brain barrier (BBB) penetration, held promise for potentially assisting in GBM treatment through the identified target genes (Figure 9D).